Posted on March 1st, 2016 by msequeira
Candidates for this position should have a PhD or MD and a strong foundation in cellular immunology, with experience in immunologic assays, flow cytometry, and animal work. Fellows will be expected to develop and test hypotheses, to design and conduct experiments, to interpret data and prepare figures for publication, and to oversee the work of research technicians, rotating students or clinical fellows.
Interested applicants should submit a CV and references to:
Sarah Adams, MD
The Victor and Ruby Hansen Surface Professor in Ovarian Cancer Research
Assistant Professor, Gynecologic Oncology
The University of New Mexico Comprehensive Cancer Center
1201 Camino de Salud NE, MSC07-4025
Albuquerque, NM 87131
Our lab investigates the impact of regional immune surveillance on the growth and dissemination of ovarian cancer. Ovarian cancer is characterized by rapid intraperitoneal dissemination and a poor overall prognosis. Notably, recurrent disease also preferentially develops in the peritoneal cavity. Using immune-competent murine models, we have defined changes in local leukocyte populations which precede tumor metastasis and specifically condition this environment for immunologic tolerance. These findings present novel therapeutic opportunities which we have leveraged in the development of a combination regimen of PARP-inhibition and immune checkpoint blockade. This protocol successfully induced immune-mediated tumor clearance and long-term survival in murine cancer models. Based on our results, a phase I/II clinical trial of this combination for women with recurrent ovarian cancer is currently underway. Ongoing work examines the role of resident lymphocyte populations as critical targets of immunotherapeutic strategies and how standard therapy disrupts the unique peritoneal tumor environment. Ultimately our goal is to provide a rationale for integrating immune regimens with current treatment protocols to improve outcomes for women with this disease.
The University of New Mexico Comprehensive Cancer Center includes 125 researchers supported by more than $72 million in federal and private research funding each year. Scientists are clustered into four National Cancer Institute (NCI) research programs. Our lab is a member of the Translational Cancer Biology and Signaling Group, which is focused on mechanistic, translational, and clinical studies of cancer biology. A current portfolio of 30 clinical trials is led by clinician scientists in the Program, including early phase investigator-initiated trials derived from Program science.
You must be logged-in to the site to post a comment.